Insulin: A Story of Innovation
On January 11, 1922—100 years ago—14-year-old Leonard Thompson, who was diagnosed with diabetes 3 years earlier, became the first person to receive insulin.
Stem Cell Replacement Therapy: Its Time has Begun
ViaCyte has results on its second stem cell-based technology, providing evidence of stem cells secreting insulin in response to meal consumption.
Progress Toward Cures: Thoughts at Year’s End from Breakthrough T1D’s CEO
Breakthrough T1D CEO Aaron Kowalski, Ph.D., weighs in on the exciting news surrounding stem cell-derived beta cell replacement therapies, now in human clinical trials.
First-in-Human Gene-Edited Stem Cell Trial? Check.
ViaCyte, a beta cell replacement company long supported by Breakthrough T1D, and CRISPR Therapeutics have a new first: Gene-editing for type 1 diabetes.
First-in-Human T1D Vaccine Trial Reports Positive Results
A first-in-human study of the coxsackie B vaccine—made by Breakthrough T1D-funded researchers Drs. Hyoty and Knip—reports positive results.
COVID-19 Vaccine Now Available for Children Ages 5+
Late Tuesday evening, Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC), recommended the use of the Pfizer/BioNTech COVID-19 vaccine in children ages 5–11. This decision followed the FDA’s Emergency Use Authorization on Friday, Oct. 29th. That means that if you have a child 5 years of age or older, they […]
Vertex Shares Data from Their Stem Cell-Derived Therapy—and It’s Outstanding
In February, Vertex announced they were beginning a clinical trial for VX-880, their stem cell-derived therapy for use in people with type 1 diabetes (T1D). Today, they announced that the first person to receive this therapy now needs 91% less insulin 90 days after receiving an infusion of these fully differentiated cells at just half […]
Vertex Pharmaceuticals Investigating Cell Therapy for Type 1 Diabetes
Vertex is currently enrolling for a clinical trial evaluating their stem cell derived islet cell infusion therapy, VX-880.
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning that it has not been approved at this time.
At ADA, Breakthrough T1D-Funded Research Takes Center Stage
There were a number of fantastic results at the ADA’s Scientific Sessions. Here is a video and a summary of the key takeaways from the conference.
